301 related articles for article (PubMed ID: 23710668)
1. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
Murata A; Amano R; Yamada N; Kimura K; Yashiro M; Nakata B; Hirakawa K
World J Surg Oncol; 2013 May; 11():117. PubMed ID: 23710668
[TBL] [Abstract][Full Text] [Related]
2. Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma.
Nakamura J; Kohya N; Kai K; Ohtaka K; Hashiguchi K; Hiraki M; Kitajima Y; Tokunaga O; Noshiro H; Miyazaki K
Int J Oncol; 2010 Oct; 37(4):845-52. PubMed ID: 20811706
[TBL] [Abstract][Full Text] [Related]
3. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
[TBL] [Abstract][Full Text] [Related]
4. Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.
Yoon KA; Woo SM; Hong EK; Jung MK; Park WS; Bae K; Han SS; Kim TH; Koh YH; Park SJ; Lee WJ
Oncology; 2015; 89(6):345-50. PubMed ID: 26418006
[TBL] [Abstract][Full Text] [Related]
5. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
Sasaki H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Br J Cancer; 2014 Sep; 111(7):1275-84. PubMed ID: 25032731
[TBL] [Abstract][Full Text] [Related]
6. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
[TBL] [Abstract][Full Text] [Related]
7. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer.
Deng T; Pan H; Han R; Huang D; Li H; Zhou L; Wang X; Bai M; Li X; Liu R; Ge S; Ning T; Zhang L; Ba Y
Int J Clin Exp Med; 2014; 7(12):5041-9. PubMed ID: 25664003
[TBL] [Abstract][Full Text] [Related]
9. Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).
Santini D; Schiavon G; Vincenzi B; Cass CE; Vasile E; Manazza AD; Catalano V; Baldi GG; Lai R; Rizzo S; Giacobino A; Chiusa L; Caraglia M; Russo A; Mackey J; Falcone A; Tonini G
Curr Cancer Drug Targets; 2011 Jan; 11(1):123-9. PubMed ID: 20578980
[TBL] [Abstract][Full Text] [Related]
10. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
[TBL] [Abstract][Full Text] [Related]
11. Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.
Kim J; Kim H; Lee JC; Kim JW; Paik WH; Lee SH; Hwang JH; Ryu JK; Kim YT
PLoS One; 2018; 13(12):e0209104. PubMed ID: 30557411
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
[TBL] [Abstract][Full Text] [Related]
13. RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin.
Chun JW; Lee B; Park WS; Han N; Hong EK; Park EY; Han SS; Park SJ; Kim TH; Lee WJ; Woo SM
J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682775
[TBL] [Abstract][Full Text] [Related]
14. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
[TBL] [Abstract][Full Text] [Related]
15. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
Giovannetti E; Del Tacca M; Mey V; Funel N; Nannizzi S; Ricci S; Orlandini C; Boggi U; Campani D; Del Chiaro M; Iannopollo M; Bevilacqua G; Mosca F; Danesi R
Cancer Res; 2006 Apr; 66(7):3928-35. PubMed ID: 16585222
[TBL] [Abstract][Full Text] [Related]
16. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
[TBL] [Abstract][Full Text] [Related]
17. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer.
Kim R; Tan A; Lai KK; Jiang J; Wang Y; Rybicki LA; Liu X
Cancer; 2011 Jul; 117(14):3126-34. PubMed ID: 21264835
[TBL] [Abstract][Full Text] [Related]
18. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
Sinn M; Riess H; Sinn BV; Stieler JM; Pelzer U; Striefler JK; Oettle H; Bahra M; Denkert C; Bläker H; Lohneis P
Eur J Cancer; 2015 Aug; 51(12):1546-54. PubMed ID: 26049689
[TBL] [Abstract][Full Text] [Related]
19. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.
Elebro J; Ben Dror L; Heby M; Nodin B; Jirström K; Eberhard J
Acta Oncol; 2016; 55(3):286-96. PubMed ID: 26362587
[TBL] [Abstract][Full Text] [Related]
20. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
Ohtaka K; Kohya N; Sato K; Kitajima Y; Ide T; Mitsuno M; Miyazaki K
Oncol Rep; 2008 Aug; 20(2):279-86. PubMed ID: 18636187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
